NASDAQ · ANAB
AnaptysBio, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ANAB: Nov 3, 2026
AnaptysBio, Inc. Common Stock is estimated to report earnings on 11/03/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $0.41. The reported EPS for the same quarter last year was $0.52.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.41 | $0.73 | $0.00 | 3 |
| Dec 2026 | $0.52 | $0.81 | $0.10 | 3 |
| Mar 2027 | $0.85 | $0.94 | $0.75 | 2 |
| Jun 2027 | $0.95 | $1.14 | $0.77 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews- Zacks · Oct 28, 9:00 AM EDTArcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings GrowthArcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 27, 9:00 AM EDTAnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 20, 3:28 AM EDTCytoDyn Appoints Robert E. Hoffman As CEO; Lalezari To Focus On Research(RTTNews) – CytoDyn Inc. (CYDY), a clinical-stage biotechnology company developing leronlimab for oncology indications, announced the appointment of Robert E. Hoffman as Chief Executive Officer (CEO), effective October 20, 2026.
- RTTNews · Oct 19, 11:24 PM EDTGSK's Jemperli Becomes First Approved Immunotherapy For MSI-H/dMMR Locally Advanced Renal Cancer(RTTNews) – GSK plc (GSK) announced that the U.S. FDA has approved Jemperli as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) locally advanced rectal cancer. The approval was granted un
- RTTNews · Sep 22, 6:23 AM EDTAnaptysBio Swings To Profit In Q2 Reflecting $181.5 Mln Tax Benefit(RTTNews) – AnaptysBio Inc. (ANAB), a clinical-stage biotechnology company, reported a profit for the second quarter of 2026, primarily driven by a significant tax benefit following its separation from First Tracks Biotherapeutics, while collaboration revenue increased on higher
- Zacks · Sep 21, 5:35 PM EDTAnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue EstimatesAnaptysBio (ANAB) delivered earnings and revenue surprises of +76.09% and +3.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 24, 11:37 AM EDTGSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal CancerGSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.
- Zacks · Aug 13, 8:45 AM EDTCorMedix (CRMD) Q2 Earnings and Revenues Top EstimatesCorMedix (CRMD) delivered earnings and revenue surprises of +11.54% and +7.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 14, 8:26 AM EDTGSK's Jemperli Delivers Promising Interim Data in Rectal CancerGSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.
- Zacks · May 21, 9:40 AM EDTIs AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.
- Zacks · May 19, 9:55 AM EDTWall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Zacks · May 14, 9:55 AM EDTAnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowAfter losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for AnaptysBio, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.